TherapeuticsMD (TXMD) EBIAT (2016 - 2025)
Historic EBIAT for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $152000.0.
- TherapeuticsMD's EBIAT rose 12495.89% to $152000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $171000.0, marking a year-over-year increase of 10504.28%. This contributed to the annual value of -$2.3 million for FY2024, which is 7750.54% up from last year.
- Latest data reveals that TherapeuticsMD reported EBIAT of $152000.0 as of Q3 2025, which was up 12495.89% from $551000.0 recorded in Q2 2025.
- In the past 5 years, TherapeuticsMD's EBIAT registered a high of $159.4 million during Q4 2022, and its lowest value of -$49.0 million during Q1 2022.
- For the 5-year period, TherapeuticsMD's EBIAT averaged around $454789.5, with its median value being -$1.1 million (2024).
- As far as peak fluctuations go, TherapeuticsMD's EBIAT soared by 47098.7% in 2022, and later plummeted by 10215.0% in 2023.
- Quarter analysis of 5 years shows TherapeuticsMD's EBIAT stood at -$43.0 million in 2021, then surged by 470.99% to $159.4 million in 2022, then tumbled by 100.55% to -$883000.0 in 2023, then skyrocketed by 113.7% to $121000.0 in 2024, then increased by 25.62% to $152000.0 in 2025.
- Its EBIAT was $152000.0 in Q3 2025, compared to $551000.0 in Q2 2025 and -$653000.0 in Q1 2025.